Selank
Tuftsin analogue · TP-7
Russian-approved anxiolytic peptide; small trials suggest benzodiazepine-like calm without sedation.
Not FDA-approved. Approved in Russia. Not FDA/EMA approved. This page describes research and public discussion; it is not a recommendation to use.
Overview
Selank is a synthetic analogue of tuftsin, an immunomodulatory peptide. It is approved in Russia for generalized anxiety disorder. Western evidence is essentially absent.
Mechanism of action
Modulates GABA-A receptor allosteric sites, enkephalin degradation, and serotonin metabolism; influences IL-6 expression.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Russian label (0.15% nasal) B Human clinical data | ~750–2,700 mcg/day | 2–3× daily | 1–3 weeks | Intranasal |
Clinical trials & studies
- RCT2008Selank vs medazepam in generalized anxiety disorder
Comparable anxiolytic effect in small trial.
Safety
Side effects
- Nasal irritation
- Fatigue
Contraindications
- Pregnancy
Interactions
- Benzodiazepines (possible potentiation)
Long-term safety
Unknown.
Regulatory status
Approved outside US
Approved in Russia. Not FDA/EMA approved.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.